Works matching IS 03407004 AND DT 2020 AND VI 69 AND IP 8
Results: 23
Correction to: Expression of the immune checkpoint VISTA in breast cancer.
- Published in:
- 2020
- By:
- Publication type:
- Correction Notice
Correction to: Human ovarian cancer intrinsic mechanisms regulate lymphocyte activation in response to immune checkpoint blockade.
- Published in:
- 2020
- By:
- Publication type:
- Correction Notice
NK1R antagonist decreases inflammation and metastasis of breast carcinoma cells metastasized to liver but not to brain; phenotype-dependent therapeutic and toxic consequences.
- Published in:
- Cancer Immunology, Immunotherapy, 2020, v. 69, n. 8, p. 1639, doi. 10.1007/s00262-020-02574-z
- By:
- Publication type:
- Article
Prevalence of PD-L1 expression is associated with EMAST, density of peritumoral T-cells and recurrence-free survival in operable non-metastatic colorectal cancer.
- Published in:
- Cancer Immunology, Immunotherapy, 2020, v. 69, n. 8, p. 1627, doi. 10.1007/s00262-020-02573-0
- By:
- Publication type:
- Article
Tumor infiltrating lymphocytes as adjuvant treatment in stage III melanoma patients with only one invaded lymph node after complete resection: results from a multicentre, randomized clinical phase III trial.
- Published in:
- Cancer Immunology, Immunotherapy, 2020, v. 69, n. 8, p. 1663, doi. 10.1007/s00262-020-02572-1
- By:
- Publication type:
- Article
Characterising the prognostic potential of HLA-DR during colorectal cancer development.
- Published in:
- Cancer Immunology, Immunotherapy, 2020, v. 69, n. 8, p. 1577, doi. 10.1007/s00262-020-02571-2
- By:
- Publication type:
- Article
Epstein–Barr virus (EBV) and polyomaviruses are detectable in oropharyngeal cancer and EBV may have prognostic impact.
- Published in:
- Cancer Immunology, Immunotherapy, 2020, v. 69, n. 8, p. 1615, doi. 10.1007/s00262-020-02570-3
- By:
- Publication type:
- Article
Outcomes with immune checkpoint inhibitors for relapsed small-cell lung cancer in a Swiss cohort.
- Published in:
- Cancer Immunology, Immunotherapy, 2020, v. 69, n. 8, p. 1605, doi. 10.1007/s00262-020-02565-0
- By:
- Publication type:
- Article
Characterization of an HLA-restricted and human cytomegalovirus-specific antibody repertoire with therapeutic potential.
- Published in:
- Cancer Immunology, Immunotherapy, 2020, v. 69, n. 8, p. 1535, doi. 10.1007/s00262-020-02564-1
- By:
- Publication type:
- Article
Tumor-infiltrating CD39+CD8+ T cells determine poor prognosis and immune evasion in clear cell renal cell carcinoma patients.
- Published in:
- Cancer Immunology, Immunotherapy, 2020, v. 69, n. 8, p. 1565, doi. 10.1007/s00262-020-02563-2
- By:
- Publication type:
- Article
Characterization of CD103+ CD8+ tissue-resident T cells in esophageal squamous cell carcinoma: may be tumor reactive and resurrected by anti-PD-1 blockade.
- Published in:
- Cancer Immunology, Immunotherapy, 2020, v. 69, n. 8, p. 1493, doi. 10.1007/s00262-020-02562-3
- By:
- Publication type:
- Article
Energy metabolism and cell motility defect in NK-cells from patients with hepatocellular carcinoma.
- Published in:
- Cancer Immunology, Immunotherapy, 2020, v. 69, n. 8, p. 1589, doi. 10.1007/s00262-020-02561-4
- By:
- Publication type:
- Article
18F-fluorodeoxyglucose positron emission tomography correlates with tumor immunometabolic phenotypes in resected lung cancer.
- Published in:
- Cancer Immunology, Immunotherapy, 2020, v. 69, n. 8, p. 1519, doi. 10.1007/s00262-020-02560-5
- By:
- Publication type:
- Article
PD-1+ natural killer cells in human non-small cell lung cancer can be activated by PD-1/PD-L1 blockade.
- Published in:
- Cancer Immunology, Immunotherapy, 2020, v. 69, n. 8, p. 1505, doi. 10.1007/s00262-020-02558-z
- By:
- Publication type:
- Article
Prognostic impact of stromal and intratumoral CD3, CD8 and FOXP3 in adjuvantly treated breast cancer: do they add information over stromal tumor-infiltrating lymphocyte density?
- Published in:
- Cancer Immunology, Immunotherapy, 2020, v. 69, n. 8, p. 1549, doi. 10.1007/s00262-020-02557-0
- By:
- Publication type:
- Article
Neuroendocrine tumours and their microenvironment.
- Published in:
- Cancer Immunology, Immunotherapy, 2020, v. 69, n. 8, p. 1449, doi. 10.1007/s00262-020-02556-1
- By:
- Publication type:
- Article
The glucocorticoids prednisone and dexamethasone differentially modulate T cell function in response to anti-PD-1 and anti-CTLA-4 immune checkpoint blockade.
- Published in:
- Cancer Immunology, Immunotherapy, 2020, v. 69, n. 8, p. 1423, doi. 10.1007/s00262-020-02555-2
- By:
- Publication type:
- Article
Expression of the immune checkpoint VISTA in breast cancer.
- Published in:
- Cancer Immunology, Immunotherapy, 2020, v. 69, n. 8, p. 1437, doi. 10.1007/s00262-020-02554-3
- By:
- Publication type:
- Article
Human ovarian cancer intrinsic mechanisms regulate lymphocyte activation in response to immune checkpoint blockade.
- Published in:
- Cancer Immunology, Immunotherapy, 2020, v. 69, n. 8, p. 1391, doi. 10.1007/s00262-020-02544-5
- By:
- Publication type:
- Article
Combined blockade of TGf-β1 and GM-CSF improves chemotherapeutic effects for pancreatic cancer by modulating tumor microenvironment.
- Published in:
- Cancer Immunology, Immunotherapy, 2020, v. 69, n. 8, p. 1477, doi. 10.1007/s00262-020-02542-7
- By:
- Publication type:
- Article
Knocking out matrix metalloproteinase 12 causes the accumulation of M2 macrophages in intestinal tumor microenvironment of mice.
- Published in:
- Cancer Immunology, Immunotherapy, 2020, v. 69, n. 8, p. 1409, doi. 10.1007/s00262-020-02538-3
- By:
- Publication type:
- Article
Interleukin-33 pretreatment promotes metastatic growth of murine melanoma by reducing the cytotoxic capacity of CD8+ T cells and enhancing regulatory T cells.
- Published in:
- Cancer Immunology, Immunotherapy, 2020, v. 69, n. 8, p. 1461, doi. 10.1007/s00262-020-02522-x
- By:
- Publication type:
- Article
A phase I study of multi-HLA-binding peptides derived from heat shock protein 70/glypican-3 and a novel combination adjuvant of hLAG-3Ig and Poly-ICLC for patients with metastatic gastrointestinal cancers: YNP01 trial.
- Published in:
- Cancer Immunology, Immunotherapy, 2020, v. 69, n. 8, p. 1651, doi. 10.1007/s00262-020-02518-7
- By:
- Publication type:
- Article